Patents Assigned to Dharmacon, Inc.
  • Methods and compositions for selecting siRNA of improved functionality
    Patent number: 8000902
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: August 16, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting TATA box binding protein (TBP)-associated factor (TAF1)
    Patent number: 7985854
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TAF1.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: July 26, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting TNF?
    Patent number: 7977471
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to TNF?.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: July 12, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • IDENTIFICATION OF MIRNA PROFILES THAT ARE DIAGNOSTIC OF HYPERTROPHIC CARDIOMYOPATHY
    Publication number: 20110160285
    Abstract: Disclosed herein are a collection of miRNAs and genes whose expression is altered in hypertrophic cardiomyopathy. Accordingly, these miRNAs and genes, singly or in combination, are useful as molecular markers for diagnosis or prognosis of hypertrophic cardiomyopathy. The miRNAs and genes disclosed can also be therapeutic targets for cardiac hypertrophy. For example, agents such as miRNA mimics, miRNA inhibitors or siRNAs for a given miRNA or gene can be used to modulate the level of these molecules thereby inhibiting or preventing hypertrophic cardiomyopathy.
    Type: Application
    Filed: March 12, 2009
    Publication date: June 30, 2011
    Applicants: THE REGENTS OF THE UNIVERSITY OF COLORADO, Dharmacon, Inc.
    Inventors: Emily Anderson, Anastasia Khvorova, Anita G. Seto, Scott Baskerville, Leslie Leinwand, Kevin G. Sullivan
  • siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
    Patent number: 7951935
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to MYC.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: May 31, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting spleen tyrosine kinase
    Publication number: 20110111983
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
    Type: Application
    Filed: December 6, 2010
    Publication date: May 12, 2011
    Applicant: DHARMACON INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe
  • siRNA targeting TNFa
    Publication number: 20110105363
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to TNF?.
    Type: Application
    Filed: December 23, 2010
    Publication date: May 5, 2011
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Apparatus and system having dry gene silencing compositions
    Patent number: 7935811
    Abstract: A reverse transfection apparatus can be used for introducing siRNA into a cell to effect gene silencing. Such an apparatus can include a well plate having a well configured for transfecting cells. The well can include a substantially dry gene silencing composition that has at least a first siRNA which silences a first target gene. The gene silencing composition can be configured such that the at least first siRNA is capable of being solubilized or suspended in an aqueous medium in an amount sufficient for transfecting cells in the well. Additionally, the at least first siRNA can include a modification or a conjugate. The reverse transfection apparatus can be provided as a kit or system that additionally includes cells, polynucleotide carriers, reverse transfection reagents, and the like.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: May 3, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Barbara Robertson, Devin Leake, Kathryn Robinson, William S. Marshall, Anastasia Khvorova
  • siRNA target hypoxia-inducible factor 1
    Patent number: 7935813
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: May 3, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • Apparatus and system having dry gene silencing pools
    Patent number: 7923207
    Abstract: A reverse transfection apparatus can be used for introducing siRNA into a cell to effect gene silencing. Such an apparatus can include a well plate having a well configured for transfecting cells. The well can include a substantially dry gene silencing composition that has at least two siRNAs which silences at least a first target gene. The gene silencing composition can be configured such that the at least two siRNAs are each capable of being solubilized or suspended in an aqueous medium in an amount sufficient for transfecting cells in the well. Additionally, the siRNAs can include a hairpin structure, modification, or a conjugate. Also, the at least siRNAs can be rationally designed. The reverse transfection apparatus can be provided as a kit or system that additionally includes cells, polynucleotide carriers, reverse transfection reagents, and the like.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: April 12, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Barbara Robertson, Devin Leake, Kathryn Robinson, William S. Marshall, Anastasia Khvorova
  • Method of determining a cellular response to a biological agent
    Patent number: 7923206
    Abstract: A method of determining a cellular response to a biological agent can be preformed in the presence of gene silencing. Such a method can include the use of siRNA in order to silence various genes in the cell in order to monitor the cellular response to the biological agent when a gene has been silenced. Accordingly, the response of a cell having a silenced gene to a biological agent can be indicative of which genes may be responsible for normal or abnormal cellular responses to various synthetic and natural biological agents such as active agents or pathogens.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: April 12, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Barbara Robertson, Devin Leake, Kathryn Robinson, William S. Marshall, Anastasia Khvorova
  • siRNA targeting TIE-2
    Publication number: 20110077173
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Application
    Filed: November 8, 2010
    Publication date: March 31, 2011
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • SiRNA targeting ras-related nuclear protein RAN
    Patent number: 7897754
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: March 1, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting spleen tyrosine kinase
    Patent number: 7893247
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: February 22, 2011
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
  • siRNA targeting connective tissue growth factor (CTGF)
    Publication number: 20110039734
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CTGF.
    Type: Application
    Filed: October 1, 2010
    Publication date: February 17, 2011
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting proto-oncogene MET
    Publication number: 20110034349
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MET.
    Type: Application
    Filed: September 8, 2010
    Publication date: February 10, 2011
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting amyloid beta (A4) precursor protein (APP)
    Publication number: 20110021382
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APP.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 27, 2011
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting Beta Secretase (BACE)
    Publication number: 20110003714
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for BACE.
    Type: Application
    Filed: August 17, 2010
    Publication date: January 6, 2011
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting apolipoprotein B (APOB)
    Publication number: 20110003713
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, composition, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB.
    Type: Application
    Filed: July 12, 2010
    Publication date: January 6, 2011
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting Survivin
    Publication number: 20100331214
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Through these methodologies, one can select siRNA that target genes, including surviving.
    Type: Application
    Filed: August 13, 2010
    Publication date: December 30, 2010
    Applicant: DHARMACON INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read